Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Grassley requests briefings on the “scope and subject matter of all pending drug company investigations.” He is concerned that settlements like the Pfizer Neurontin deal are viewed as a cost of doing business.